Fig. 2From: Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in ChinaKM and parametric survival distributions for iDFS iDFS, invasive disease-free survival; ABE + ET: abemaciclib + endocrine therapy; ET: endocrine therapyBack to article page